AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
(in millions, except per share data) | Quarter Ended March 31, 2023 | Full-Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q1 2023 acquired IPR&D and milestones expense | $ | — | $ | 2.39 | $ | 2.49 | $ | — | $ | 10.70 | $ | 11.10 | |||||||||||||||||||||||
Q1 2023 acquired IPR&D and milestones expense | 150 | (0.08) | (0.08) | 150 | (0.08) | (0.08) | |||||||||||||||||||||||||||||
Guidance including Q1 2023 acquired IPR&D and milestones expensea | $ | 150 | $ | 2.31 | $ | 2.41 | $ | 150 | $ | 10.62 | $ | 11.02 |
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2023, as both cannot be reliably forecasted.
1